Continual obstructive pulmonary illness (COPD) is a continual inflammatory lung illness characterised by coughing, the manufacturing of extra sputum, and dyspnea. Sufferers with excessively thick sputum could have frequent assaults or develop extra severe illness. The rules advocate airway clearance for sufferers with extreme sputum who’re hospitalized with COPD. The lively cycle of respiratory approach is the commonest non-pharmacological airway clearance approach utilized by physiotherapists. Nevertheless, the effectiveness of the approach shouldn’t be at all times assured. Energetic cycle of respiratory methods require the preliminary dilution of the sputum, normally by inhalation medicine, which can have restricted results.
We suggest a single-blind randomized managed trial utilizing 75 hospitalized sufferers recognized with COPD with extreme sputum manufacturing. The sufferers might be divided into three teams. The intervention group will obtain lively cycle of respiratory methods mixed with phonophoresis. The 2 comparability teams might be handled with lively cycle of respiratory methods and phonophoresis, respectively. This system might be applied day by day for 1 week. The first outcomes might be adjustments in sputum viscosity and manufacturing, lung operate, and pulse oximetry.
Secondary outcomes embody the evaluation of COPD and anxiousness, measured by the COPD Evaluation Take a look at scale and the Nervousness Stock for Respiratory Illness, respectively; self-satisfaction; the diploma of cooperation; and the size of hospital keep. All final result measures, except for sputum manufacturing and extra secondary outcomes, might be assessed on the graduation of the examine and after 1 week’s intervention. Evaluation of variance might be used to research variations between the teams, and a p-value of lower than 0.05 (two-tailed) might be thought-about statistically vital.
Current research have discovered that phonophoresis decreases irritation, suggesting the potential of the mixed utilization of lively cycle of respiratory methods and phonophoresis. Subsequently, the intention of this examine is to discover the effectiveness and security of mixing lively cycle of respiratory approach and phonophoresis in treating COPD sufferers. This examine introduces a mixture of lively cycle of respiratory methods and phonophoresis to discover the affect of those interventions on sufferers hospitalized with COPD. If this mixed intervention is proven to be efficient, it could show to be a greater therapy for sufferers with COPD.
The impact of consecutive ambient air air pollution on the hospital admission from continual obstructive pulmonary illness within the Chengdu area, China
Hospitalisation dangers for continual obstructive pulmonary illness (COPD) have been attributed to ambient air air pollution worldwide. Nevertheless, an increase in COPD hospitalisations could point out a substantial enhance in fatality charge in public well being. The present examine focuses on the affiliation between consecutive ambient air air pollution (CAAP) and COPD hospitalisation to supply predictable early steering in the direction of estimates of COPD hospital admissions within the occasion of consecutive publicity to air air pollution.
Massive knowledge analytics had been collected from 3-year time collection recordings (from 2015 to 2017) of each air knowledge and COPD hospitalisation knowledge within the Chengdu area in China. Based mostly on the mixed results of CAAP and unit enhance in air pollutant concentrations, a quasi-Poisson regression mannequin was established, which revealed the affiliation between CAAP and estimated COPD admissions. The outcomes present the dynamics and outbreaks within the variations in COPD admissions in response to CAAP. Cross-validation and imply squared error (MSE) are utilized to validate the goodness of match.
In each short-term and long-term air air pollution exposures, Z check outcomes present that the COPD hospitalisation threat is larger for males than for ladies; equally, the prevalence of COPD hospital admissions within the group of aged individuals (> 65 years outdated) is considerably bigger than that in decrease age teams. The time lag between the air high quality and COPD hospitalisation can also be investigated, and a peak of COPD hospitalisation threat is discovered to lag 2 days for air high quality index (AQI) and PM10, and 1 day for PM2.5. The massive data-based predictive paradigm could be a measure for the early detection of a public well being occasion in post-COVID-19. The examine findings also can present steering for COPD admissions within the occasion of consecutive publicity to air air pollution within the Chengdu area.
Harnessing cell well being know-how to help lengthy–time period continual sickness administration: exploring household caregiver help wants within the outpatient setting
Household caregiving is a crucial public well being subject, significantly with the getting old inhabitants. Lately, cell well being (mHealth) know-how has emerged as a possible low-cost, scalable platform to handle caregiver help wants, and thereby alleviate the burden on caregivers. This examine sought to look at the help wants of household caregivers of their lived experiences of outpatient care to tell the event of a future mHealth intervention. We performed 20 semi-structured interviews in 2 outpatient hematopoietic cell transplant (HCT) clinics at a big tutorial medical heart within the Midwestern United States. A thematic evaluation was carried out to outline rising themes.
Qualitative knowledge evaluation recognized 5 main themes that HCT caregivers confronted: (I) life-style restrictions as a result of affected person’s immunocompromised state; (II) Unmet wants attributable to limitations within the present assets, together with unfamiliar medical duties with out crucial trainings; and (III) caregivers’ adaptive methods, together with reformation of social relationships with household and buddies. Based mostly on these findings, we recommend Three design issues to information the event of a future mHealth intervention.
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E02C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E02C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E06C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E06C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E06C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Goat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E08C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E08C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Dog Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E08C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E07C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E07C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E07C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Porcine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rat Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A12043 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Canine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A64387 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A29522 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E04C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E04C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E04C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Rabbit Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E03C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E03C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E03C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A73101 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Sheep Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A99249 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Bovine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A81820 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E09C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E09C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E09C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Monkey Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A20784 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Porcine Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A55672 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Chicken Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A90543 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Guinea Pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E01A38237 |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E05C1802-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A sandwich ELISA for quantitative measurement of Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E05C1802-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A sandwich ELISA for quantitative measurement of Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) ELISA kit |
E05C1802-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A sandwich ELISA for quantitative measurement of Guinea pig Chronic lymphocytic leukemia up regulated protein 1(CLLU1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Chronic lymphocytic leukemia up-regulated protein 1 (CLLU1) ELISA Kit |
abx507323-96tests |
Abbexa |
96 tests |
EUR 687.5 |
CLLU1 (untagged)-Human chronic lymphocytic leukemia up-regulated 1 (CLLU1) |
SC302372 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CLLU1 (GFP-tagged) - Human chronic lymphocytic leukemia up-regulated 1 (CLLU1) |
RG220420 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CLLU1 (Myc-DDK-tagged)-Human chronic lymphocytic leukemia up-regulated 1 (CLLU1) |
RC220420 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CLLU1OS (untagged)-Human chronic lymphocytic leukemia up-regulated 1 opposite strand (CLLU1OS) |
SC302371 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Human chronic lymphocytic leukemia up-regulated 1 (CLLU1), mGFP tagged |
RC220420L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
CLLU1OS (GFP-tagged) - Human chronic lymphocytic leukemia up-regulated 1 opposite strand (CLLU1OS) |
RG212117 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF clone of Human chronic lymphocytic leukemia up-regulated 1 (CLLU1), Myc-DDK-tagged |
RC220420L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Human Putative chronic lymphocytic leukemia up-regulated protein 1 opposite strand transcript protein (CLLU1-AS1) ELISA Kit |
abx507403-96tests |
Abbexa |
96 tests |
EUR 687.5 |
CLLU1OS (Myc-DDK-tagged)-Human chronic lymphocytic leukemia up-regulated 1 opposite strand (CLLU1OS) |
RC212117 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Chronic Lymphocytic Leukemia Deletion Region Gene 8 Protein (CLLD8) Antibody |
abx430501-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
Chronic Lymphocytic Leukemia Deletion Region Gene 8 Protein (CLLD8) Antibody |
abx430501-200l |
Abbexa |
200 µl |
EUR 387.5 |
Lenti ORF clone of Human chronic lymphocytic leukemia up-regulated 1 opposite strand (CLLU1OS), mGFP tagged |
RC212117L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL |
BNUB2035-100 |
Biotium |
100uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 0.2mg/mL |
BNUB2035-500 |
Biotium |
500uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL |
BNUB2046-100 |
Biotium |
100uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 0.2mg/mL |
BNUB2046-500 |
Biotium |
500uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL |
BNUB2047-100 |
Biotium |
1uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 0.2mg/mL |
BNUB2047-500 |
Biotium |
1uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 1mg/mL |
BNUM2035-50 |
Biotium |
1uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 1mg/mL |
BNUM2046-50 |
Biotium |
1uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), 1mg/mL |
BNUM2047-50 |
Biotium |
1uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNUB2035-50 |
Biotium |
50uL |
EUR 486 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), 1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNUB2046-50 |
Biotium |
50uL |
EUR 486 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), 1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC702035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC702035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC702046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC702046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF770 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC802035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC802035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC802046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC802046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC812035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC812035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC812046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC812046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF680R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC552035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC552035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC552046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC552046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF555 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC612035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC612035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC612046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC612046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF660R conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC432035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC432035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC432046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC432046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF543 conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC052035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNC052035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC052046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNC052046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF405M conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCA2035-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), APC conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCA2046-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), APC conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCAP2035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCAP2035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCAP2046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCAP2046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCH2035-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCH2035-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCH2046-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCH2046-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCP2035-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), PerCP conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCP2046-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), PerCP conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035) Antibody |
BNCR2035-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), RPE conjugate, Concentration: 0.1mg/mL |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046) Antibody |
BNCR2046-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), RPE conjugate, Concentration: 0.1mg/mL |
Lenti ORF particles, CLLU1 (mGFP-tagged) - Human chronic lymphocytic leukemia up-regulated 1 (CLLU1), 200ul, >10^7 TU/mL |
RC220420L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF clone of Human chronic lymphocytic leukemia up-regulated 1 opposite strand (CLLU1OS), Myc-DDK-tagged |
RC212117L3 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, CLLU1 (Myc-DDK tagged) - Human chronic lymphocytic leukemia up-regulated 1 (CLLU1), 200ul, >10^7 TU/mL |
RC220420L3V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Anti-ZAP70 (Chronic Lymphocytic Leukemia Marker) Monoclonal Antibody |
M00754-1 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Mouse Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody. Validated in IHC and tested in Human. |
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: 2F3.2 |
APR14717G |
Leading Biology |
7 ml |
EUR 580.8 |
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone 2F3.2. This antibody is applicable in IHC, IF, FC |
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
RA0453-C.1 |
ScyTek Laboratories |
0.1 ml |
EUR 60.07 |
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
RA0453-C.5 |
ScyTek Laboratories |
0.5 ml |
EUR 200.66 |
ZAP-70 (Chronic Lymphocytic Leukemia Marker); Clone ZAP70/528 (Concentrate) |
RA0453-C1 |
ScyTek Laboratories |
1 ml |
EUR 361.66 |
Monoclonal ZAP70 (Chronic Lymphocytic Leukemia Marker) Antibody, Clone: SPM362 |
APR14716G |
Leading Biology |
7 ml |
EUR 580.8 |
Description: A Monoclonal antibody against Human ZAP70 (Chronic Lymphocytic Leukemia Marker). The antibodies are raised in Mouse and are from clone SPM362. This antibody is applicable in IHC, IF, FC |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, 0.1mg/mL |
BNC682035-100 |
Biotium |
100uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF568 conjugate, 0.1mg/mL |
BNC682035-500 |
Biotium |
500uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, 0.1mg/mL |
BNC682046-100 |
Biotium |
100uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF568 conjugate, 0.1mg/mL |
BNC682046-500 |
Biotium |
500uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), CF568 conjugate, 0.1mg/mL |
BNC682047-100 |
Biotium |
1uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), CF568 conjugate, 0.1mg/mL |
BNC682047-500 |
Biotium |
1uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, 0.1mg/mL |
BNC472035-100 |
Biotium |
100uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF647 conjugate, 0.1mg/mL |
BNC472035-500 |
Biotium |
500uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, 0.1mg/mL |
BNC472046-100 |
Biotium |
100uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2046), CF647 conjugate, 0.1mg/mL |
BNC472046-500 |
Biotium |
500uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), CF647 conjugate, 0.1mg/mL |
BNC472047-100 |
Biotium |
1uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker)(ZAP70/2047), CF647 conjugate, 0.1mg/mL |
BNC472047-500 |
Biotium |
1uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF594 conjugate, 0.1mg/mL |
BNC942035-100 |
Biotium |
100uL |
EUR 192 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
ZAP70 (Chronic Lymphocytic Leukemia Marker) (ZAP70/2035), CF594 conjugate, 0.1mg/mL |
BNC942035-500 |
Biotium |
500uL |
EUR 532 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
The findings herein captured the household caregiver’s lived experiences throughout outpatient care. There was broad settlement that caregiving was difficult and disturbing. Thus, efficient and scalable interventions to help caregivers are wanted. This examine offered knowledge to information the content material and design of a future mHealth intervention within the outpatient setting.